Razazi K, Labbe V, Laine L, Bedet A, Carteaux G, de Prost N
Front Cardiovasc Med. 2022; 9:951016.
PMID: 36158835
PMC: 9500364.
DOI: 10.3389/fcvm.2022.951016.
Shete V, Liu N, Jia Y, Viswakarma N, Reddy J, Thimmapaya B
Int J Mol Sci. 2018; 19(12).
PMID: 30469494
PMC: 6321386.
DOI: 10.3390/ijms19123704.
Levine T, Levine A, ELLIOTT W, Narins B, Stomel R
Clin Cardiol. 2001; 24(3):231-6.
PMID: 11288970
PMC: 6654832.
DOI: 10.1002/clc.4960240311.
Fitton A, Brogden R
Drugs Aging. 1994; 4(5):417-41.
PMID: 8043944
DOI: 10.2165/00002512-199404050-00007.
Bruckner R, Scholz H
Br J Pharmacol. 1984; 82(1):223-32.
PMID: 6329389
PMC: 1987239.
DOI: 10.1111/j.1476-5381.1984.tb16462.x.
Intracellular calcium in heart failure.
Morgan J
Cardiovasc Drugs Ther. 1988; 1(6):621-4.
PMID: 3154328
DOI: 10.1007/BF02125749.
[Alpha-adrenoceptors in the myocardium: incidence and functional significance].
Mugge A
Klin Wochenschr. 1985; 63(21):1087-97.
PMID: 3001400
DOI: 10.1007/BF02291089.
Phorbol ester does not mimic, but antagonizes the alpha-adrenoceptor-mediated positive inotropic effect in the rabbit papillary muscle.
KUSHIDA H, Hiramoto T, Satoh H, Endoh M
Naunyn Schmiedebergs Arch Pharmacol. 1988; 337(2):169-76.
PMID: 2897086
DOI: 10.1007/BF00169245.
Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.
Colucci W, Denniss A, Leatherman G, Quigg R, Ludmer P, Marsh J
J Clin Invest. 1988; 81(4):1103-10.
PMID: 2832444
PMC: 329637.
DOI: 10.1172/JCI113423.
Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside.
Hasenfuss G, Holubarsch C, Heiss H, Rattert B, Just H
Basic Res Cardiol. 1989; 84 Suppl 1:225-33.
PMID: 2818456
DOI: 10.1007/BF02650362.
Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations.
Hasenfuss G, Holubarsch C, Blanchard E, MULIERI L, ALPERT N, Just H
Basic Res Cardiol. 1989; 84 Suppl 1:147-55.
PMID: 2818454
DOI: 10.1007/BF02650354.
Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
von der Leyen H
Klin Wochenschr. 1989; 67(12):605-15.
PMID: 2671473
DOI: 10.1007/BF01718141.
Regulation of force and intracellular calcium transients by cyclic AMP generated by forskolin, MDL 17,043 and isoprenaline, and its modulation by muscarinic receptor agents: a novel mechanism for accentuated antagonism.
Endoh M
Basic Res Cardiol. 1989; 84 Suppl 1:69-83.
PMID: 2554874
DOI: 10.1007/BF02650348.
Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.
Barnett D
Br J Clin Pharmacol. 1989; 27(5):527-37.
PMID: 2547407
PMC: 1379917.
DOI: 10.1111/j.1365-2125.1989.tb03414.x.
Calcium sensitisers.
Lee J, Allen D
BMJ. 1990; 300(6724):551-2.
PMID: 2108746
PMC: 1662365.
DOI: 10.1136/bmj.300.6724.551.
Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.
Dorszewski A, Kling L, Sponer G
Br J Pharmacol. 1990; 101(3):686-90.
PMID: 2076485
PMC: 1917742.
DOI: 10.1111/j.1476-5381.1990.tb14141.x.
Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole.
Gwathmey J, Warren S, BRIGGS G, Copelas L, Feldman M, Phillips P
J Clin Invest. 1991; 87(3):1023-31.
PMID: 1999483
PMC: 329896.
DOI: 10.1172/JCI115061.
[Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for the therapy with inotropic drugs].
Bohm M, Schwinger R, Erdmann E
Klin Wochenschr. 1990; 68(18):887-95.
PMID: 1979643
DOI: 10.1007/BF01649033.
Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure.
Perreault C, Shannon R, Komamura K, Vatner S, Morgan J
J Clin Invest. 1992; 89(3):932-8.
PMID: 1311723
PMC: 442940.
DOI: 10.1172/JCI115674.
Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.
Fischer T, Erbel R, Treese N
Drugs. 1992; 44(6):928-45.
PMID: 1282864
DOI: 10.2165/00003495-199244060-00003.